“有病去医院，有事找法院”！王老吉和加多宝又“打起来了”

Core Viewpoint - The trademark dispute between Wanglaoji and JDB has extended to the global market, with both companies claiming ownership of the "Wanglaoji" trademark overseas, leading to escalating tensions and legal actions [1][4]. Group 1: Trademark Ownership Claims - JDB claims to have registered the "Wanglaoji" trademark in over 60 countries and regions worldwide, emphasizing its legal victories in Canada and the EU [2][4]. - Wanglaoji asserts that the trademark belongs to Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., with a clear historical lineage and legal documentation supporting their claim [4][10]. - As of September 30, Wanglaoji has completed trademark registrations in over 100 countries and regions, while JDB's claims are characterized as "malicious registration" by Wanglaoji [4][10]. Group 2: Legal Actions and Responses - The dispute intensified after JDB announced its overseas trademark victories on September 30, prompting Wanglaoji to issue a statement accusing JDB of misleading the public [2][4]. - Following a series of legal battles in China, a court ruled in 2023 that JDB infringed on Wanglaoji's trademark rights, ordering JDB to pay 317 million yuan in damages [10]. - The ongoing trademark battle is seen as a strategic move by both companies to secure their positions in the shrinking domestic market while expanding internationally [10]. Group 3: Market Strategies - JDB has established a production base overseas since 2016, achieving approximately 10% of its sales from international markets [10]. - Wanglaoji is actively working to make international sales a significant part of its revenue, aiming for a single market to contribute around 1 billion yuan [12]. - Both companies have adopted different strategies for their foreign trademarks, with JDB using names that resonate with overseas Chinese consumers, while Wanglaoji has introduced the "WALOVI" brand to establish an independent international identity [10][11].